Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Dose, Sequential-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ALXN1101 in Healthy Adult Subjects

NCT01894165 is registered in ClinicalTrials.gov with Origin Biosciences as lead sponsor.

NCT NCT01894165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01894165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Dose, Sequential-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ALXN1101 in Healthy Adult Subjects
Lead sponsor
Origin Biosciences
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2013
Completion date
September 30, 2013
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

deficiency of activity of molybdenum-dependent enzymes (sulfite oxidase [sox], xanthine dehydrogenase, and aldehyde oxidase), molybdenum cofactor deficiency (mocd), rare autosomal recessive disorder